Israel’s Compugen has signed a discovery and license agreement with Roche to identify genetic variations to predict drug response to rheumatoid arthritis (RA) treatments.

Compugen will use its GeneVa platform to analyze DNA samples and data provided by Roche.

Compugen’s GeneVa platform incorporates an in silico database of approximately 200,000 predicted nonsingle nucleotide polymorphism genetic variations, according to Compugen.

Financial terms of the agreement were not disclosed.